J&J medtech sales rise 2.5% as orthopedics spinoff weighs
JJohnson & Johnson said medical technology sales rose 2.5% but missed estimates, while it is leaning toward spinning off its orthopedics business. The combination puts pressure on J&J to show that portfolio restructuring can offset slower growth in a major operating segment.
JJNJ+0.88%1D close3M · CLOSING PRICES2026-10-12 CLOSE
The story
Johnson & Johnson reported a 2.5% increase in medical technology sales, below estimates, and is leaning toward a spinoff of its orthopedics business, according to Bloomberg Television on Oct. 13.
The update points to two separate developments in J&J’s medtech portfolio: weaker-than-expected sales growth and a possible change in ownership for orthopedics. The timing and structure of any transaction remain open.
J&J’s full-year 2025 revenue was $94.2 billion, up 6.0% year over year, with a 28.5% net margin and diluted EPS of $11.03. Those figures cover the broader company and an earlier period, rather than the reported medtech result.
The immediate unresolved points are the size and scope of the proposed orthopedics spinoff, its timing, and whether the segment’s sales trajectory improves. Future company updates should clarify the portfolio plan and provide the next comparable medtech sales figure.
Our take
1 / 6
Our read · Oct 13
Johnson & Johnson’s medtech sales rose 2.5% as it leaned toward spinning off its orthopedics business.
Why
The setup is mixed: slower-than-expected medtech growth raises execution questions, while a possible orthopedics separation could sharpen J&J’s portfolio. J&J’s FY2025 revenue was $94.2 billion, up 6.0% year over year, with a 28.5% net margin, but those broader and older figures do not resolve the segment-level question.
What could change this view
The read changes if J&J abandons the orthopedics spinoff or reports a materially different medtech sales trajectory at its next update.
▲ The case it holds
A separation could give J&J a more focused portfolio and allow the remaining businesses to be evaluated against the company’s $94.2 billion FY2025 revenue base.
▼ The case it breaks
The reported 2.5% medtech sales increase missed estimates, and the spinoff may not offset weaker operating momentum or execution costs.
Prices: 1D EOD · OCT 12 CLOSE, licensed end-of-day data.
Source: Bloomberg Television · Published here TUE, OCT 13 · 9:36 AM ET · the only report in this record · How this is decided →
Kept as written · your side, if you take one, is graded privately against licensed closes after 10 trading days · reaction = the first close after a story against the close before it · nothing here is advice · How the Wire is made →